StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research report released on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock.
Pulmatrix Stock Performance
Shares of NASDAQ:PULM opened at $2.09 on Wednesday. Pulmatrix has a 12-month low of $1.55 and a 12-month high of $3.14. The business has a 50 day moving average of $1.86 and a 200-day moving average of $1.88.
Pulmatrix (NASDAQ:PULM – Get Free Report) last issued its quarterly earnings data on Thursday, March 28th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter. Pulmatrix had a negative return on equity of 63.94% and a negative net margin of 193.49%. The firm had revenue of $2.20 million for the quarter.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Read More
- Five stocks we like better than Pulmatrix
- Learn Technical Analysis Skills to Master the Stock Market
- High-Yield Texas Instruments Could Hit New Highs Soon
- Consumer Staples Stocks, Explained
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
